HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

glutamyl-glutamic acid (Glu-Glu)

RN given for (L,L)-isomer
Also Known As:
Glu-Glu; dipotassium glutamyl-glutamate
Networked: 66 relevant articles (1 outcomes, 6 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Matsuo, Keitaro: 4 articles (06/2016 - 03/2002)
2. Hosono, Satoyo: 3 articles (06/2016 - 08/2010)
3. Ito, Hidemi: 3 articles (06/2016 - 08/2010)
4. Oze, Isao: 3 articles (06/2016 - 08/2010)
5. Tanaka, Hideo: 3 articles (06/2016 - 08/2010)
6. Watanabe, Miki: 3 articles (06/2016 - 08/2010)
7. Yatabe, Yasushi: 3 articles (06/2016 - 08/2010)
8. Tajima, Kazuo: 3 articles (07/2013 - 03/2002)
9. Chen, Jiansong: 2 articles (01/2017 - 03/2016)
10. Lu, Jiachun: 2 articles (01/2017 - 03/2016)

Related Diseases

1. Ehrlich Tumor Carcinoma
2. Breast Neoplasms (Breast Cancer)
04/01/2013 - "Meta-analysis of total studies showed that the NBS1 Glu185Gln variant carriers were not susceptible to breast cancer (ORGln vs. Glu = 1.05, 95 % CI 0.80-1.39, P OR = 0.719; OR Gln/Gln vs. Glu/Glu = 0.82, 95 % CI 0.62-1.08, P OR = 0.154; OR Glu/Gln vs. Glu/Glu = 1.00, 95 % CI 0.90-1.13, P OR = 0.939; ORGln/Gln + Glu/Gln vs. Glu/Glu = 0.96, 95 % CI 0.83-1.11, P OR = 0.551; ORGln/Gln vs. Glu/Glu + Glu/Gln = 0.84, 95 % CI 0.67-1.05, P OR = 0.134). "
09/01/2010 - "The Malay, Chinese and Indian women who were Glu/Glu homozygotes (P= 0.419, 0.093, 0.367), Ala/Glu heterozygotes (P= 0.648, 0.182, 0.402) and carriers of Glu allele (P= 0.402, 0.079, 0.349), respectively, were not associated with breast cancer risk. "
04/01/2013 - "Overall, no significant associations were found between MTHFR Glu429Ala polymorphism and breast cancer risk when all studies were pooled into the meta-analysis (Glu/Glu vs Ala/Ala: OR = 0.891, 95 % CI = 0.782-1.015; Glu/Ala vs Ala/Ala: OR = 0.874, 95 % CI = 0.760-1.006; dominant model: OR = 0.885, 95 % CI = 0.775-1.012; and recessive model: OR = 0.989, 95 % CI = 0.931-1.051). "
04/01/2013 - "In the subgroup analysis by ethnicity, significantly elevated breast cancer risk was associated with Glu/Glu variant genotype in homozygote comparison and recessive genetic model (Glu/Glu vs Ala/Ala: OR = 0.78, 95 % CI = 0.63-0.97; Glu/Glu vs Glu/Ala: OR = 0.92, 95 % CI = 0.85-0.99; recessive model: OR = 0.91, 95 % CI = 0.85-0.97), while no significant associations were found for all comparison models in other ethnicity populations. "
3. Asthma (Bronchial Asthma)
08/01/2005 - "Results for Gln/Glu27 in adults seem to indicate that heterozygotes are at decreased risk of asthma than either homozygote (odds ratio = 0.73, 95% CI: 0.62, 0.87), although the studies are heterogeneous; in children, the Glu/Glu genotype has a decreased risk of asthma (odds ratio = 0.60, 95% CI: 0.35, 0.99) compared with the other genotypes. "
03/01/2013 - "The number of overall asthma exacerbations and the proportion of children with these events were similar among β2AR genotypes at position 16 (Arg/Arg, Arg/Gly, and Gly/Gly) and at position 27 (Gln/Gln, Gln/Glu, and Glu/Glu). "
01/01/2018 - "The presence of heterozygous Arg-Gly and Gln-Glu gives a better response to drug therapy than the presence of Gly-Gly and Glu-Glu genotypes at codons 16 and 27.ConclusionPolymorphism of β2AR at codons 16 and 27 correlates with asthma severity and response to treatment in asthmatic children."
03/01/2008 - "The distribution frequencies of the Arg/Arg and Gly/Gly homozygotes and the Arg/Gly heterozygote at the 16th locus of beta2-AR gene were 13.9%, 13.4% and 72.7%, respectively, and the frequencies of the Gln/Gln and Glu/Glu homozygotes and the Glu/Glu heterozygote at the 27th locus were 13.9%, 4.3% and 81.8%, respectively, and the frequencies of the II, DD and ID genotypes of ACE gene were 49.3%, 20.0% and 30.7%, respectively; and an interaction of multiplication model could exist between the air pollutants, PM4 , SO2, and CO, and the beta2-AR and ACE polymorphisms for the occurrence of childhood asthma (P < 0.05 for all indicators). "
4. Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome)
5. Schizophrenia (Dementia Praecox)

Related Drugs and Biologics

1. Cancer Vaccines
2. Antibodies
3. alanylalanine (Ala-Ala)
4. Peptides (Polypeptides)
5. Plasminogen Inactivators
6. Tissue Plasminogen Activator (Alteplase)
7. gamma-Aminobutyric Acid (GABA)
8. glutamylalanine
9. lysyllysine (Lys-Lys)
10. aspartyl-aspartic acid (Asp-Asp)

Related Therapies and Procedures

1. Therapeutics
2. Drug Therapy (Chemotherapy)